{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:13:11Z","timestamp":1790190791672,"version":"4.1.0"},"reference-count":117,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disease in which immunoglobulin G (IgG) antibodies (Abs) bind to acetylcholine receptors (AChR) or to functionally related molecules in the postsynaptic membrane at the neuromuscular junction. IgG crystallizable fragment (Fc)-mediated effector functions, such as antibody-dependent complement deposition, contribute to disease development and progression. Despite progress in understanding Ab-mediated disease mechanisms, immunotherapy of MG remained rather unspecific with corticosteroids and maintenance with immunosuppressants as first choice drugs for most patients. More specific therapeutic IgG Fc-based platforms that reduce serum half-life or effector functions of pathogenic MG-related Abs are currently being developed, tested in clinical trials or have recently been successfully translated into the clinic. In this review, we illustrate mechanisms of action and clinical efficacies of emerging Fc-mediated therapeutics such as neonatal Fc receptor (FcRn)-targeting agents. Furthermore, we evaluate prospects of therapies targeting classical Fc receptors that have shown promising therapeutic efficacy in other antibody-mediated conditions. Increased availability of Fc- and Fc receptor-targeting biologics might foster the development of personalized immunotherapies with the potential to induce sustained disease remission in patients with MG.<\/jats:p>","DOI":"10.3390\/ijms22115755","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T23:16:46Z","timestamp":1622157406000},"page":"5755","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-0003","authenticated-orcid":false,"given":"Christian W.","family":"Keller","sequence":"first","affiliation":[{"name":"Department of Neurology with Institute of Translational Neurology, University Hospital M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[{"name":"Department of Neurology with Institute of Translational Neurology, University Hospital M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[{"name":"Department of Neurology with Institute of Translational Neurology, University Hospital M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-708X","authenticated-orcid":false,"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[{"name":"Department of Neurology with Institute of Translational Neurology, University Hospital M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor","volume":"22","author":"Loutrari","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"REGAIN Study Group Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune Response to Acetylcholine Receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","article-title":"Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens","volume":"12","author":"Zisimopoulou","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2014A potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Katarzyna","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ana.410320419","article-title":"Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma","volume":"32","author":"Aarli","year":"1992","journal-title":"Ann. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"49","author":"Romi","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis","volume":"72","author":"Cruz","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1084\/jem.168.1.127","article-title":"Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q","volume":"168","author":"Bindon","year":"1988","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.molimm.2011.04.024","article-title":"Complement activation by (auto-) antibodies","volume":"48","author":"Daha","year":"2011","journal-title":"Mol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","article-title":"Thymus and autoimmunity","volume":"43","author":"Marx","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The Integrated Genomic Landscape of Thymic Epithelial Tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0165-5728(02)00145-5","article-title":"Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules","volume":"128","author":"Romi","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1172\/JCI2068","article-title":"A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes","volume":"101","author":"Nagvekar","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(78)90073-9","article-title":"In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis","volume":"311","author":"Vincent","year":"1978","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"163","author":"Tzartos","year":"1998","journal-title":"Immunol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kordas, G., Lagoumintzis, G., Sideris, S., Poulas, K., and Tzartos, S.J. (2014). Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108327"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement associated pathogenic mechanisms in myasthenia gravis","volume":"12","author":"Christadoss","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and precision medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate Degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014Autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","article-title":"LRP4 Serves as a Coreceptor of Agrin","volume":"60","author":"Zhang","year":"2008","journal-title":"Neuron"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1242\/dev.02696","article-title":"LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction","volume":"133","author":"Weatherbee","year":"2006","journal-title":"Development"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature11348","article-title":"Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses","volume":"489","author":"Yumoto","year":"2012","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor\u2013related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/08820139.2017.1299754","article-title":"Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL\/6 Mice","volume":"46","author":"Ulusoy","year":"2017","journal-title":"Immunol. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/nyas.13502","article-title":"\u00c1ngeles; Gallardo, E. Diagnostic utility of cortactin antibodies in myasthenia gravis","volume":"1412","author":"Illa","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS Guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1542\/peds.2013-0814","article-title":"Clinical Characteristics of Pediatric Myasthenia: A Surveillance Study","volume":"132","author":"VanderPluym","year":"2013","journal-title":"Pediatrics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.spen.2017.04.003","article-title":"Pediatric Myasthenia Gravis","volume":"24","author":"Peragallo","year":"2017","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejpn.2017.04.003","article-title":"Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of Juvenile Myasthenia Gravis","volume":"11","author":"Ramdas","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.nmd.2019.11.008","article-title":"Paediatric myasthenia gravis: Prognostic factors for drug free remission","volume":"30","author":"Vecchio","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/mus.21195","article-title":"Juvenile myasthenia gravis","volume":"39","author":"Chiang","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0037-1603775","article-title":"Outcome after Robotic-Assisted Thymectomy in Children and Adolescents with Acetylcholine Receptor Antibody-Positive Juvenile Myasthenia Gravis","volume":"48","author":"Kaiser","year":"2017","journal-title":"Neuropediatrics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WCO.0000000000000775","article-title":"Ocular myasthenia gravis: Updates on an elusive target","volume":"33","author":"Melson","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00063030-200115060-00003","article-title":"Immunosuppressive treatment of ocular myasthenia gravis","volume":"15","author":"Tackenberg","year":"2001","journal-title":"BioDrugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0960-8966(98)00077-7","article-title":"Juvenile myasthenia gravis with prepubertal onset","volume":"8","author":"Evoli","year":"1998","journal-title":"Neuromuscul. Disord."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1426","DOI":"10.1212\/WNL.0000000000010209","article-title":"Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis","volume":"95","author":"Tomschik","year":"2020","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","article-title":"MYACOR Study Group Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial","volume":"78","author":"Sharshar","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2014Mode of action and clinical efficacy","volume":"11","author":"Nimmerjahn","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Efficacy of Intravenous Immunoglobulin in Neurological Diseases","volume":"13","author":"Quast","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Siddiqi, Z.A., Khan, W., and Hussain, F.S. (2021). Rituximab in Myasthenia Gravis\u2014Where do we stand?. Expert. Opin. Biol. Ther., 1\u201311.","DOI":"10.1080\/14712598.2021.1889509"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/19420862.2018.1522178","article-title":"Antigen binding allosterically promotes Fc receptor recognition","volume":"11","author":"Zhao","year":"2019","journal-title":"mAbs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1056\/NEJMc1701027","article-title":"Myasthenia Gravis","volume":"376","author":"Gilhus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2016.02.006","article-title":"Targeting Fc\u03b3Rs to treat antibody-dependent autoimmunity","volume":"15","author":"Yu","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2013.12.014","article-title":"Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis","volume":"52","author":"Thiruppathi","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2016001917","article-title":"A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b","volume":"1","author":"Zhou","year":"2017","journal-title":"Blood Adv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2017.08.004","article-title":"Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease","volume":"84","author":"Sun","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"365ra158","DOI":"10.1126\/scitranslmed.aaf9418","article-title":"Elucidating the interplay between IgG-Fc valency and Fc\u03b3R activation for the design of immune complex inhibitors","volume":"8","author":"Ortiz","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM198605083141907","article-title":"Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody","volume":"314","author":"Clarkson","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/toxsci\/kfr278","article-title":"Nonclinical Evaluation of GMA161\u2014An Antihuman CD16 (Fc\u03b3RIII) Monoclonal Antibody for Treatment of Autoimmune Disorders in CD16 Transgenic Mice","volume":"125","author":"Flaherty","year":"2011","journal-title":"Toxicol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1182\/blood.V114.22.2404.2404","article-title":"3G8 and GMA161, Anti Fc\u03b3RIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies)","volume":"114","author":"Nakar","year":"2009","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V120.21.3388.3388","article-title":"Interim Results from a Phase Ib\/IIa Clinical Trial with the Soluble Fc-Gamma IIb Receptor SM101 for the Treatment of Primary Immune Thrombocytopenia","volume":"120","author":"Konstaninova","year":"2012","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000420999.09001.f7","article-title":"Evidence-based guideline: IV immunoglobulin in the treatment of neuromuscular disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"79","author":"Li","year":"2012","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000502818","article-title":"A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate\/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations","volume":"81","author":"Karelis","year":"2019","journal-title":"Eur. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: Getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/s10875-014-0018-3","article-title":"Fc Glycan-Modulated Immunoglobulin G Effector Functions","volume":"34","author":"Quast","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/6179","article-title":"Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity","volume":"17","author":"Moudry","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/bit.20151","article-title":"Establishment ofFUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"87","author":"Kinoshita","year":"2004","journal-title":"Biotechnol. Bioeng."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1172\/JCI82695","article-title":"Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity","volume":"125","author":"Quast","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3389\/fimmu.2017.00646","article-title":"Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity","volume":"8","author":"Peschke","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.2862","article-title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc\u03b3RIIB and dectin-1","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/intimm\/10.9.1289","article-title":"Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice","volume":"10","author":"Borvak","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2031352a0","article-title":"A Theoretical Model of Gamma-Globulin Catabolism","volume":"203","author":"Brambell","year":"1964","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"159s","DOI":"10.1083\/jcb.99.1.159s","article-title":"Receptor-mediated transport of IgG","volume":"99","author":"Rodewald","year":"1984","journal-title":"J. Cell Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.autrev.2016.07.035","article-title":"Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs","volume":"15","author":"Bosques","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor\u2013targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Efgartigimod MG Study Group Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"MG0002 Investigators Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Sheridan, D., Yu, Z.-X., Zhang, Y., Patel, R., Sun, F., Lasaro, M.A., Bouchard, K., Andrien, B., Marozsan, A., and Wang, Y. (2018). Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195909"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Sampei, Z., Haraya, K., Tachibana, T., Fukuzawa, T., Shida-Kawazoe, M., Gan, S.W., Shimizu, Y., Ruike, Y., Feng, S., and Kuramochi, T. (2018). Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0209509"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor\u2013experienced adult patients with PNH: The 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5755\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:23Z","timestamp":1760162963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":117,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115755"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115755","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}